Bevacizumab with PRGN-2012 for recurrent respiratory papillomatosis
Treatments studied
Part of Cancer, Ear, nose & throat, Infections, Lungs & breathing clinical trials.
This trial combines two drugs, bevacizumab (Avastin) and PRGN-2012, to see if they control throat and airway growths linked to recurrent respiratory papillomatosis. You must have already tried PRGN-2012 before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had 2 or more surgeries or used IV bevacizumab for RRP in the last year.
- You've been treated with PRGN-2012 before.
- You are in good general health (able to do daily activities, with healthy blood counts, liver, kidney, and clotting function).
- You are willing to avoid pregnancy or fathering a child during the study, and women must not breastfeed.
- You do not have recent heart or blood vessel problems, serious bleeding, or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
This trial tests whether a booster shot of the Gardasil-9 vaccine can help adults with recurrent respiratory papillomatosis (RRP) go longer between treatments. If you've already had the full vaccine series more than two years ago and still have RRP flare-ups, this booster might reduce how often you need surgery.
This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).
This Phase 1 trial is testing a vaccine made from your own immune cells (dendritic cells) that may help your body fight the virus causing recurrent papillomas in your voice box. It is for people whose papillomas are caused by HPV type 6, who have had at least one recurrence in the past year.
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Hear when a new Human Papillomavirus (HPV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.